BMC Cancer: Multicenter data to explore clinical prognostic factors for the benefit of nivolumab in previously treated metastatic gastric cancer patients

Although nivolumab (PD-1 inhibitor) is a promising treatment for advancedgastric cancer (AGC), but its efficacy is still limited

Although nivolumab (PD-1 inhibitor) is a promising treatment for advancedgastric cancer (AGC), but its efficacy is still limited

From October 2017 to December 2018, 58 patients were enrolled

From October 2017 to December 2018, 58 patients were enrolled

Of the 58 patients treated with nivolumab, none achieved CR, 4 achieved PR (7%), 17 achieved SD (29%), and the remaining 37 achieved PD (64%), resulting in an ORR of 7% , the disease control rate (DCR) was 36%

Efficacy assessment

DCR was significantly associated with ECOG PS=0 (p = 0.

DCR was significantly associated with ECOG PS=0 (p = 0.

Thirty-one (53%) patients experienced a TRAE; 18 (31%) patients were grade 2 or higher

Median OS was 5.

PFS and OS

After progression on nivolumab, median OS was 9.

After progression on nivolumab, median OS was 9.

Differences in OS with and without subsequent chemotherapy

In the Cox proportional hazards regression model, the following variables were determined to be significantly associated with poor prognosis: ECOG PS ≥1 (p = 0.

In the Cox proportional hazards regression model, the following variables were determined to be significantly associated with poor prognosis: ECOG PS ≥1 (p = 0.

Taken together, studies suggest that nivolumab may not be effective for AGC in patients with poor physical status and a history of trastuzumab therapy
.
Studies have shown that nivolumab may not be effective for AGC in patients with poor physical status and a history of trastuzumab therapy
.
Studies have shown that nivolumab may not be effective for AGC in patients with poor physical status and a history of trastuzumab therapy
.

Original source:

Original source:

Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, ​​Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H.
Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
BMC Cancer.
2022 Jan 3;22(1):22.
doi: 10.
1186/s12885-021-09118-3.
PMID: 34980017 ; PMCID: PMC8721909.

Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, ​​Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H.
Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
BMC Cancer.
2022 Jan 3;22(1):22.
doi: 10.
1186/s12885-021-09118-3.
PMID: 34980017 ; PMCID: PMC8721909.


Leave a message here